Evidence map›Paper›PMID 29877318›Full record

ReviewActa pharmacologica Sinica2018

Role of oxylipins in cardiovascular diseases.

Mohammed A Nayeem

Open access · bronzeAbstract readReview
In one paragraph

Review in Acta pharmacologica Sinica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 152 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. The Emerging Parkinson's Disease Oxylipin-Ome.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  5. Article
  6. Obesity is associated with distinct oxylipins in heart failure with preserved ejection fraction.Metabolomics : Official journal of the Metabolomic Society · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Comprehensive Plasma Oxylipin Profiling Reveals a Pro-Inflammatory Eicosanoid Signature and Diagnostic Biomarker Panel in Dilated Cardiomyopathy.Medical science monitor : international medical journal of experimental and clinical research · 2025
    Article
  14. Article
  15. Review
  16. Article
  17. ACAD10 and ACAD11 enable mammalian 4-hydroxy acid lipid catabolism.Nature structural & molecular biology · 2025
    Article
  18. Article
  19. Article
  20. Article

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Mohammed A NayeemDepartment of Pharmaceutical Sciences, School of Pharmacy, Center for Basic and Translational Stroke Research, Member of Toxicology Working Group and Inhalation Facilities, West Virginia University, Morgantown, USA. mnayeem@hsc.wvu.edu.
West Virginia University · US

Funding

Role of Cyp2j-epoxygenases, sEH and PPARs in adenosine-induced vascular responseR01HL114559 · NHLBI · WEST VIRGINIA UNIVERSITY · PI NAYEEM, MOHAMMED A · 2013 to 2017
$1.5M
NHLBI NIH HHS R01 HL114559
6 · The paper itself

Abstract

Globally, cardiovascular diseases (CVDs) are the number one cause of mortality. Approximately 18 million people died from CVDs in 2015, representing more than 30% of all global deaths. New diagnostic tools and therapies are eagerly required to decrease the prevalence of CVDs related to mortality and/or risk factors leading to CVDs. Oxylipins are a group of metabolites, generated via oxygenation of polyunsaturated fatty acids that are involved in inflammation, immunity, and vascular functions, etc. Thus far, over 100 oxylipins have been identified, and have overlapping and interconnected roles. Important CVD pathologies such as hyperlipidemia, hypertension, thrombosis, hemostasis and diabetes have been linked to abnormal oxylipin signaling. Oxylipins represent a new era of risk markers and/or therapeutic targets in several diseases including CVDs. The role of many oxylipins in the progression or regression in CVD, however, is still not fully understood. An increased knowledge of the role of these oxygenated polyunsaturated fatty acids in cardiovascular dysfunctions or CVDs including hypertension could possibly lead to the development of biomarkers for the detection and their treatment in the future.

Indexed as

AnimalsCardiovascular DiseasesHumansOxylipinsOxylipinsadenosine receptorscardiac oxylipinscardiovascular diseasescirculating biomarkerscoronary reactive hyperemiaCYP-epoxygenaseshypertensionplasma oxylipinssoluble epoxide hydrolase

Identifiers

PMID29877318
PMCPMC6289399
OpenAlexW2806285808

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.